Pharmaceutical

NICE endorses CSL Vifor’s sparsentan for IgA nephropathy in adults

The NICE has issued final draft guidance endorsing the use of CSL Vifor's Filspari (sparsentan) for primary IgA nephropathy.

May 24, 2025 - 06:00
NICE endorses CSL Vifor’s sparsentan for IgA nephropathy in adults
The NICE has issued final draft guidance endorsing the use of CSL Vifor's Filspari (sparsentan) for primary IgA nephropathy.
Read the original article

Tags:

Previous Article

ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%

Next Article

Obesity therapies and the multi-indication momentum: how industry is responding

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Francis deSouza’s tenure at Illumina is a lesson in how not to handle CEO succession

STAT+: Francis deSouza’s tenure at Illumina is a lesson...

Jun 12, 2023

STAT+: Updated data show long-term benefits of CRISPR treatment for sickle cell, beta thalassemia

STAT+: Updated data show long-term benefits of CRISPR t...

Jun 10, 2023

Voxzogo given green-light to treat children under five by US FDA

Voxzogo given green-light to treat children under five ...

Oct 23, 2023